<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202952</url>
  </required_header>
  <id_info>
    <org_study_id>HEC110114-P-02</org_study_id>
    <nct_id>NCT04202952</nct_id>
  </id_info>
  <brief_title>The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects</brief_title>
  <acronym>HEC110114</acronym>
  <official_title>A Phase Ib/IIa, Single Center, Randomized, Open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability， Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending&#xD;
      Dose Study to Access the Tolerability，Pharmacokinetics and Pharmacodynamics of HEC110114&#xD;
      Tablets in HCV-infected Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 24 evaluable patients will be enrolled in this study. The study randomly divided&#xD;
      into three dose groups and HEC110114 tablets planned dose levels are 600, 800, and 1200 mg,&#xD;
      sofosbuvir tablets planned dose levels are 400 mg .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Actual">August 27, 2020</completion_date>
  <primary_completion_date type="Actual">August 27, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From Days 1-10</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>At pre-defined intervals from Days 1-7</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>At pre-defined intervals from Days 1-7</time_frame>
    <description>Time to Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 T1/2 T1/2 T1/2</measure>
    <time_frame>At pre-defined intervals from Days 1-7</time_frame>
    <description>Apparent Half-Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>At pre-defined intervals from Days 1-7</time_frame>
    <description>Area Under the Plasma Concentration vs Time Curve to Last Measurable Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA</measure>
    <time_frame>At pre-defined intervals from Days 1-10</time_frame>
    <description>HCV RNA declined from baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>600 mg multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 600 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 800 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1200 mg multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 1200 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC110114 Tablet</intervention_name>
    <description>administered orally once daily</description>
    <arm_group_label>600 mg multiple doses</arm_group_label>
    <arm_group_label>800 mg multiple doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir Tablet</intervention_name>
    <description>administered orally once daily</description>
    <arm_group_label>1200 mg multiple doses</arm_group_label>
    <arm_group_label>600 mg multiple doses</arm_group_label>
    <arm_group_label>800 mg multiple doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign the informed consent form before the trial and fully understand the contents of&#xD;
             the trial, the process and possible adverse reactions;&#xD;
&#xD;
          -  Be able to complete the study according to the trail protocol;&#xD;
&#xD;
          -  Subjects (including partners) have no pregnancy plan within six months after the last&#xD;
             dose of study drug and voluntarily take effective contraceptive measures;&#xD;
&#xD;
          -  Male subjects and must be 18 to 65 years of age inclusive;&#xD;
&#xD;
          -  Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive, and a body weight ≥50&#xD;
             kg for males and ≥45 kg for females;&#xD;
&#xD;
          -  No previous treatment with any direct-acting antiviral (DAA) drugs for HCV, such as&#xD;
             Simeprevir, Sofosbuvir, Daclatasvir etc;&#xD;
&#xD;
          -  HCV RNA ≥10*5 IU/mL at screening (Roche COBAS Taqman);&#xD;
&#xD;
          -  Chronic genotype 1-6 HCV Infection, multiple genotypes, subtype unidentifiable or&#xD;
             others ;&#xD;
&#xD;
          -  Serum ALT ≤5 times ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergies constitution ( multiple drug and food allergies);&#xD;
&#xD;
          -  History of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25&#xD;
             mL of spirits or 100 mL of wine);&#xD;
&#xD;
          -  Donation or loss of blood over 450 mL within 3 months prior to screening;&#xD;
&#xD;
          -  History of any non-HCV liver diseases, including but not limited to hemochromatosis,&#xD;
             primary biliary cirrhosis, Wilson's disease, autoimmune hepatitis, drug or alcoholic&#xD;
             hepatitis, non-alcoholic steatohepatitis, etc;&#xD;
&#xD;
          -  12-lead ECG with clinically significant;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 mL/min;&#xD;
&#xD;
          -  Subjects deemed unsuitable by the investigator for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junqi Niu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yanhua Ding, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <state>Changchun</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

